BNP PARIBAS FINANCIAL MARKETS - ARBUTUS BIOPHARMA CORP ownership

ARBUTUS BIOPHARMA CORP's ticker is ABUS and the CUSIP is 03879J100. A total of 66 filers reported holding ARBUTUS BIOPHARMA CORP in Q3 2020. The put-call ratio across all filers is 1.33 and the average weighting 0.1%.

Quarter-by-quarter ownership
BNP PARIBAS FINANCIAL MARKETS ownership history of ARBUTUS BIOPHARMA CORP
ValueSharesWeighting
Q3 2023$491,869
+25.2%
242,300
+41.9%
0.00%
Q2 2023$392,780
+51.4%
170,774
+99.5%
0.00%
Q1 2023$259,380
+454.8%
85,604
+326.6%
0.00%
Q4 2022$46,751
-99.9%
20,065
-48.1%
0.00%
Q3 2022$73,856,000
+14.3%
38,668
+62.2%
0.00%
Q2 2022$64,596,000
+180.0%
23,836
+207.8%
0.00%
Q1 2022$23,074,000
-76.1%
7,743
-68.8%
0.00%
Q4 2021$96,690,000
+43.1%
24,856
+57.8%
0.00%
Q3 2021$67,589,000
+246.5%
15,755
+144.8%
0.00%
Q2 2021$19,504,000
+177209.1%
6,437
+107183.3%
0.00%
Q2 2020$11,000
-84.5%
6
-91.4%
0.00%
Q1 2020$71,000
-63.6%
700.0%0.00%
Q4 2019$195,000
-96.8%
70
-98.2%
0.00%
Q3 2019$6,042,000
-26.7%
3,9620.0%0.00%
Q2 2019$8,241,000
-68.7%
3,962
-46.1%
0.00%
Q1 2019$26,302,000
+141.0%
7,347
+536.1%
0.00%
Q3 2018$10,915,000
+29.4%
1,1550.0%0.00%
Q2 2018$8,432,0001,1550.00%
Other shareholders
ARBUTUS BIOPHARMA CORP shareholders Q3 2020
NameSharesValueWeighting ↓
JACOB ASSET MANAGEMENT OF NEW YORK LLC 260,000$866,0000.34%
RTW INVESTMENTS, LP 5,978,355$19,908,0000.31%
GSA CAPITAL PARTNERS LLP 309,839$1,032,0000.17%
QCM Cayman, Ltd. 12,728$42,0000.13%
COWEN AND COMPANY, LLC 486,717$1,621,0000.11%
Hudson Bay Capital Management LP 1,400,000$4,662,0000.06%
Kerrisdale Advisers, LLC 208,150$693,0000.05%
Secure Asset Management, LLC 10,000$33,0000.02%
PDT Partners, LLC 72,500$241,0000.02%
Point72 Asset Management, L.P. 1,037,700$3,456,0000.02%
View complete list of ARBUTUS BIOPHARMA CORP shareholders